- Home
- NTIP vs KPTI Comparison
NTIP vs KPTI Comparison
Compare NTIP & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NTIP | KPTI |
|---|---|---|
| Founded | 1990 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.3M | 36.7M |
| IPO Year | 2013 | 2013 |
Fundamental Metrics
Financial Performance| Metric | NTIP | KPTI |
|---|---|---|
| Price | $1.56 | $0.53 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.25 |
| AVG Volume (30 Days) | 9.7K | ★ 1.3M |
| Earning Date | 11-05-2026 | 11-02-2026 |
| Dividend Yield | ★ 6.33% | N/A |
| EPS Growth | ★ 15.38 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $150,000.00 | ★ $146,067,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $27.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 50.00 | 0.57 |
| 52 Week Low | $1.24 | $0.31 |
| 52 Week High | $1.75 | $10.99 |
Technical Indicators
Market Signals| Indicator | NTIP | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 53.62 | 30.41 |
| Support Level | $1.41 | $0.31 |
| Resistance Level | $1.65 | $2.16 |
| Average True Range (ATR) | 0.07 | 0.09 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 64.29 | 44.67 |
Price Performance
Historical ComparisonAbout NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).